Last reviewed · How we verify
NCT01472107: APL0511
Study on Number and Outcome of Pregnancy in Acute Promielocitic Leukaemia (APL) Patients Treated With Chemotherapy
trial in Acute Promyelocytic Leukemia in 69 participants. Completed in 14 June 2019.
14 June 2019
Quick facts
| Lead sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 69 |
| Start date | 7 March 2012 |
| Primary completion | 14 June 2019 |
| Estimated completion | 14 June 2019 |
| Sites | 36 locations across Italy |
Conditions studied
- Acute Promyelocytic Leukemia — all drugs for Acute Promyelocytic Leukemia →
- Pregnancy — all drugs for Pregnancy →
Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto — full company profile →
Who can join
Adults 18 to 50, female only, with Acute Promyelocytic Leukemia or Pregnancy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The GIMEMA FOUNDATION promotes an observational (retrospective) study on number and outcome of pregnancy in childbearing age female patients treated with chemotherapy for APL. These patients were enrolled in studies AIDA0493, AIDA2000 and were in CR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01472107
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Promyelocytic Leukemia
Currently open trials in the same condition.
- NCT05832320 — Optimum Induction Therapy of Low-risk APL · NA · recruiting
- NCT04687176 — Frontline Oral Arsenic Trioxide for APL · Phase 2 · recruiting
- NCT04793919 — Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia · Phase 2 · recruiting
Other Gruppo Italiano Malattie EMatologiche dell'Adulto trials
Trials by the same sponsor.
- NCT07356960 — Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world · not yet recruiting
- NCT07158294 — Identification of BCR::ABL1 Mutations by Digital PCR in CML · NA · not yet recruiting
- NCT07249606 — Momelotinib Effectiveness in Myelofibrosis · not yet recruiting
- NCT06880601 — Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple Myeloma · Phase 2 · not yet recruiting
- NCT06657846 — HRQoL and Financial Toxicity in Patients With VEXAS Syndrome · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01472107 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Gruppo Italiano Malattie EMatologiche dell'Adulto
- Last refreshed: 12 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01472107.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing